Do xanthine oxidase inhibitors reduce both left ventricular hypertrophy and endothelial dysfunction in cardiovascular patients with renal dysfunction?
- Conditions
- Chronic kidney disease (CKD) and left ventricular hypertrophy (LVH)Circulatory SystemComplications and ill-defined descriptions of heart disease
- Registration Number
- ISRCTN45773760
- Lead Sponsor
- niversity of Dundee (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
1. Both males and females, age >18 years old and there is no upper age limit
2. Chronic kidney disease, Stage 3 (estimated glomerular filtration rate [GFR] 30-60 ml/min)
3. Echo left ventricular hypertrophy
1. Known cardiac failure with left ventricular ejection fraction (LVEF) <45%
2. Patients already on allopurinol
3. Patients who have gout
4. Patients with severe hepatic disease
5. Usual contraindications to magnetic resonance imaging (MRI), including any metal implants in the body and severe claustrophobia
6. Current immunosuppressive therapy (e.g., azathioprine, ciclosporin or cyclophosphamide), chlorpropamide, theophylline or 6-mercaptopurine
7. Malignancy or other life threatening disease
8. Pregnancy and lactating women
9. Patients unable to provide informed consent (e.g., learning difficulties)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in left ventricular hypertrophy at 9 months
- Secondary Outcome Measures
Name Time Method Reduction in endothelial dysfunction at 9 months